natgillin/translations-raw huggingface dataset:
The bishydrochloride monohydrate salt of the compound of formula (I) or the pharmaceutical composition for use according to claim 5, wherein said condition is selected from dementias, and further wherein said dementias are selected from: dementias of the Alzheimer's type (DAT); Alzheimer's disease; Pick's disease; vascular dementias; Lewy-body disease; dementias due to metabolic, toxic and deficiency diseases, including alcoholism, hypothyroidism, and vitamin B12 deficiency; AIDS-dementia complex; Creutzfeld-Jacob disease; or atypical subacute spongiform encephalopathy. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 6, naznačen time što je navedeno stanje odabrano od demencija, i pri čemu su navedene demencije dalje odabrane od: demencija Alzheimerovog tipa (DAT); Alzheimerove bolesti; Pickove bolesti; vaskularnih demencija; bolesti Lewyjevih tjelešaca; demencija uzrokovanih metaboličkim, toksičnim i bolestima deficijencije, uključujući alkoholizam, hipotireozu i nedostatak vitamina B12; kompleksa AIDS-demencija; Creutzfeld-Jacobove bolesti; ili atipične subakutne spongiformne encefalopatije.
The bishydrochloride monohydrate salt of the compound of formula (I) or the pharmaceutical composition for use according to claim 4, wherein said condition is selected from parkinsonism and movement disorders, and further wherein said parkinsonism and movement disorders are selected from: Parkinson's disease; multiple system atrophy; progressive supranuclear palsy; corticobasal degeneration; hepatolenticular degeneration; chorea, including Huntington's disease and hemiballismus; athetosis; dystonias, including spasmodic torticollis, occupational movement disorder, and Gilles de la Tourette syndrome; tardive or drug induced dyskinesias, including levodopa-induced dyskinesia; tremor; or myoclonus. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 6, naznačen time što je navedeno stanje odabrano od parkinsonizma i poremećaja kretanja, i pri čemu su navedeni parkinsonizam i poremećaji kretanja dalje odabrani od: Parkinsonove bolesti, multiple atrofije sustava, progresivne supranuklearne paralize, kortikobazalne degeneracije; hepatolentikularne degeneracije; koreje, uključujući Huntingtonovu bolest i hemibalizam; atetoze; distonija, uključujući spastični tortikolis, profesionalni poremećaj kretanja, i Gilles de la Tourette sindrom; zakašnjele ili diskinezije izazvane lijekom, uključujući diskineziju izazvanu levodopom; treskavice; ili mioklonusa.
A process for producing a liquid fuel from a gas containing at least about 50% methane by volume, said process comprising: 
Postupak proizvodnje tekućeg goriva iz plina koji sadrži najmanje otprilike 50 % metana, volumno, naznačen time što se navedeni postupak sastoji u:
contacting said gas with (i) a liquid feedstock consisting of crude oil or a liquid petroleum fraction and (ii) a metallic catalyst grid, both said liquid feedstock and said metallic catalyst grid contained in a reaction vessel, at a temperature of about 80°C or above but below the boiling temperature of said crude oil, said metallic catalyst grid comprising windings of a transition metal supported on an iron frame; 
stavljanju u kontakt navedenog plina s (i) tekućom sirovinom koja se sastoji od sirove nafte ili tekuće naftne frakcije i (ii) rešetkom metalnog katalizatora, gdje se i navedena tekuća sirovina i navedena rešetka metalnog katalizatora nalaze u reakcijskoj posudi, na temperaturi od otprilike 80 °C ili iznad, no ispod temperature vrenja navedene sirove nafte, gdje navedena rešetka metalnog katalizatora sadrži namotaje od prijelaznog metala koje nosi željezni okvir;
The process of claim 1 wherein gas is natural gas and said liquid feedstock is crude oil or diesel oil. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je plin zemni plin, a navedena tekuća sirovina je sirova nafta ili dizelsko ulje.
The process of claim 1 wherein said liquid feedstock occupies a portion of said reaction vessel and thereby forms a liquid level in said reaction vessel and a head space above said liquid level, said metallic catalyst grid resides in said head space, step (a) comprises feeding said gas to said reaction vessel under said liquid level, and step (b) comprises recovering said gaseous reaction product from said head space. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedena tekuća sirovina zauzima dio navedene reakcijske posude i tako tvori razinu tekućine u navedenoj reakcijskoj posudi i slobodni prostor iznad navedene razine tekućine, gdje se navedena rešetka metalnog katalizatora nalazi u navedenom slobodnom prostoru, korak (a) se sastoji u dovođenju navedenog plina u navedenu reakcijsku posudu ispod navedene razine tekućine, a korak (b) se sastoji u prikupljanju navedenog produkta plinovite reakcije iz navedenog slobodnog prostora.
The process of claim 1 wherein step (a) is performed at a temperature of from about 150°C to about 200°C and a pressure of from about 1 atmosphere to about 1.5 atmospheres. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se korak (a) provodi na temperaturi od otprilike 150 °C do otprilike 200 °C i pod tlakom od otprilike 1 atmosfere (101,3 kPa) do otprilike 1,5 atmosfera (152 kPa).
The process of claim 1 wherein the frame is circular in outer diameter with reinforcing bars or rods within the perimeter and the windings converge at the center of the frame. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je okvir u obliku kruga u vanjskom promjeru, s ojačavajućim šipkama ili štapovima unutar oboda, a namotaji se sreću u središtu okvira.
passing a second gas containing at least about 50% methane by volume through said first condensate and a metallic catalyst grid, both said first condensate and said metallic catalyst grid contained in a second reaction vessel, with said first condensate at a temperature of about 80°C or above but below the boiling temperature of said first condensate, said metallic catalyst grid comprising windings of a transition metal supported on an iron frame; 
propuštanje drugog plina koji sadrži najmanje otprilike 50 % metana, volumno, kroz navedeni prvi kondenzat i rešetku metalnog katalizatora, gdje se i navedeni prvi kondenzat i navedena rešetka metalnog katalizatora nalaze u drugoj reakcijskoj posudi, gdje je navedeni prvi kondenzat na temperaturi od otprilike 80 °C ili iznad, no ispod temperature vrenja od navedenog prvog kondenzata, gdje navedena rešetka metalnog katalizatora sadrži namotaje od prijelaznog metala koje nosi željezni okvir;
The process of claim 8 wherein said liquid feedstock is crude oil and said first gas and said second gas are both natural gas. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je navedena tekuća sirovina sirova nafta, a navedeni prvi plin i navedeni drugi plin su oba zemni plin.
A process for transporting crude oil through a pipeline, said process comprising: 
Postupak transportiranja sirove nafte kroz cjevovod, naznačen time što se navedeni postupak sastoji u:
contacting a gas containing at least about 50% methane by volume with (i) a liquid feedstock consisting of crude oil or a liquid petroleum fraction and (ii) a metallic catalyst grid, both said liquid feedstock and said metallic catalyst grid contained in a reaction vessel, at a temperature of about 80°C or above but below the boiling temperature of said crude oil, said metallic catalyst grid comprising windings of a transition metal supported on an iron frame; 
stavljanju u kontakt plina koji sadrži najmanje otprilike 50 % metana, volumno, s (i) tekućom sirovinom koja se sastoji od sirove nafte ili tekuće naftne frakcije i (ii) rešetkom metalnog katalizatora, gdje se i navedena tekuća sirovina i navedena rešetka metalnog katalizatora nalaze u reakcijskoj posudi, na temperaturi od otprilike 80 °C ili iznad, no ispod temperature vrenja navedene sirove nafte, gdje navedena rešetka metalnog katalizatora sadrži namotaje od prijelaznog metala koje nosi željezni okvir;
condensing said gaseous reaction product to said liquid fuel; 
kondenziranju navedenog produkta plinovite reakcije u navedeno tekuće gorivo;
blending said crude oil with the resulting liquid fuel to form a blend; and 
miješanju navedene sirove nafte s dobivenim tekućim gorivom kako bi se dobilo smjesu; i
The process of claim 10 wherein step (d) is performed at a temperature of from about 150°C to about 200°C and a pressure of from about 1 atmosphere to about 1.5 atmospheres. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se korak (d) provodi na temperaturi od otprilike 150 °C do otprilike 200 °C i pod tlakom od otprilike 1 atmosfere (101,3 kPa) do otprilike 1,5 atmosfera (152 kPa).
making a rodent using the modified ES cell obtained in (a). 
kreiranje glodavac uz upotrebu modificirane stanice ES dobivene u (a).
A method of assessing the therapeutic efficacy of a drug targeting human cells, comprising: 
Postupak procjenjivanja terapijske djelotvornosti lijeka koji ciljano djeluje na ljudske stanice, naznačen time što se sastoji u:
monitoring the human cells in the rodent to determine the therapeutic efficacy of the drug candidate. 
praćenju ljudskih stanica u glodavcu kako bi se odredilo terapijsku djelotvornost kandidatnog lijeka.
wherein the rodent is a rat and is homozygous for the humanized SIRPa gene. The rodent of claim 1, wherein the extracellular portion of the human SIRPa protein comprises amino acid residues 28-362 of the human SIRPa protein. The rodent of claim 1, wherein the human SIRPa protein comprises the amino acid sequence as set forth in SEQ ID NO: 4. 
Glodavac u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni ljudski protein SIRPa sadrži aminokiselinski slijed kao što je iznijeto u SEQ ID NO: 4. Glodavac u skladu s patentnim zahtjevom 3, naznačen time što navedeni humanizirani protein SIRPa sadrži aminokiselinske ostatke 28-362 u SEQ ID NO: 4.
Apparatus according to any of claims 1 to 5, characterized in that a cam follower engaging a cam is connected to the actuator for moving the metering member (10,101,102,103). 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je pokretač ekscentriciteta koji međudjeluje s grebenom spojen s aktuatorom za pomicanje dozirnog elementa (10,101,102,103).
An antibody-drug conjugate wherein an antitumor compound represented by the following formula: is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: 
Antitijelo-lijek konjugat gdje antitumorski spoj predstavljen sljedećom formulom: je konjugirano sa anti-HER2 antitijelom preko veznika koji ima strukturu predstavljenu sljedećom formulom:
at least one isoxazoline active agent of Formula (I): wherein: 
najmanje jednu djelatnu tvar izoksazolina formule (I): u kojoj:
A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CR3 and N, provided that at most 3 of A1, A2, A3, A4, A5 and A6 are N; 
, A2, A3, A4, A5 i A6 su neovisno odabrani iz skupine koja se sastoji od CR3 iN, uz uvjet da najviše tri od A1, A2, A3, A4, A5 i A6 budu N;
B1, B2 and B3 are independently selected from the group consisting of CR2 and N; 
, B2 i B3 su neovisno odabrani iz skupine koja se sastoji od CR2 i N;
a pharmaceutically acceptable carrier that is suitable for the application to the skin of an animal; and wherein the carrier comprises dimethyl isosorbide. 
farmaceutski prihvatljiv nosač koji je prikladan za primjenu na koži životinje, pri čemu navedeni nosač obuhvaća dialkilester od C10-C22-dikarboksilne kiseline.
pooling fractions comprising the polypeptide in the chromatography effluent from steps a) and b). 
puliranja frakcija koje obuhvaćaju protutijelo u kromatografskom efluentu iz koraka a) i b).
The method of any one of claims 1-6 wherein the composition is loaded onto the chromatography material at about the dynamic binding capacities of the chromatography materials for the one or more contaminants. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time da se sastav puni u kromatografski materijal pri otprilike dinamičkim kapacitetima vezivanja kromatografskih materijala za jednog ili više kontaminanata.
The method of any one of claims 1-13, wherein the composition is an eluent from an affinity chromatography, a cation exchange chromatography, an anion exchange chromatography, a mixed mode chromatography or a hydrophobic interaction chromatography. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time da je sastav eluent iz afinitetne kromatografije, kromatografije kationske izmjene, kromatografije anionske izmjene, kromatografije mješovitog načina rada ili kromatografije hidrofobne interakcije.
The system as claimed in claim 1 wherein each electro-discharge nozzle (2b) further comprises a reflector disposed at the inlet, the reflector being movable to act as a check valve to admit water into the discharge chamber and to reflect a shockwave generated by the discharge. 
Sustav prema zahtjevu 1, pri čemu elektroerozijska mlaznica (2b) dalje obuhvaća reflektor smješten na izlazu, koji se može micati i tako ponašati kao kontrolni ventil u svrhu primitka vode u izbojnu komoru i odbijanja udarnog vala nastalog pomoću izboja (pražnjenja).
The system as claimed in claim 1 wherein the first and second electrodes (2b.1, 2b.2) are orthogonal to the exit orifice (2c) and wherein the first electrode (2b.1) has a planar tip and the second electrode (2b.2) has a pointed tip. 
Sustav prema zahtjevu 1, pri čemu su prva i druga elektroda (2b.1, 2b.2) postavljene ortogonalno u odnosu na izlazni otvor (2c) te pri čemu prva elektroda (2b.1) ima ravan, a druga (2b.2) šiljasti vrh.
The system as claimed in claim 2 further comprising an ultrasonic transducer for modulating a high-speed waterjet to generate a forced pulsed waterjet. 
Sustav prema zahtjevu 2, koji dalje obuhvaća ultrazvučni pretvornik za moduliranje brzog i stvaranje pulsiranog mlaza vode.
The system as claimed in claim 6 wherein a microtip of the ultrasonic transducer is orthogonal to the first and second electrodes (2b.1, 2b.2) and wherein the microtip, the first electrode (2b.1) and the second electrode (2b.2) each terminate in a diverging section. 
Sustav prema zahtjevu 6, pri čemu je mikrovrh ultrazvučnog pretvornika položen ortogonalno na prvu i drugu elektrodu (2b.1, 2b.2) i pri čemu mikrorvrh te prva (2b.1) i druga elektroda (2b.1) završavaju na proširenom dijelu.
The method as claimed in claim 12 comprising electrically insulating the electro-discharge nozzle (2b) from a water pump (33) by an electrically insulating coupling, the water pump (33) pressurizing the water to create a high-speed waterjet through the exit orifice. 
Metoda prema zahtjevu 12, koja obuhvaća električnu izolaciju elektroerozijske mlaznice (2b) od vodene pumpe (33) putem spojke za električnu izolaciju, s tim da vodena pumpa (33) stavlja vodu pod tlak u svrhu stvaranja mlaza vode kroz izlazni otvor (2c).
The wear component (10) of any of the previous claims wherein the working portion (24) is a seat for receiving and supporting a wear member (12) on the earthmoving equipment. 
Komponenta za habanje (10) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da je radni dio (24) sjedalo za prihvaćanje i podupiranje habajućeg elementa (12) na opremi za zemljane radove.
The wear component (10) of claim 1, 2 or 3 wherein the working portion (24) is a wearable surface to contact the ground during operation of the earthmoving equipment. 
Komponenta za habanje (10) u skladu s patentnim zahtjevom 1, 2 ili 3, naznačena time, da je radni dio (24) habajuća površina koja dolazi u dodir s tlom za vrijeme rada opreme za zemljane radove.
A parasiticidal composition in the form of an injectable formulation, said composition comprising an aryloazol-2-yl-cyanoethylamine compound of the formula (I): wherein: 
Paraziticidni sastav, naznačen time, da je u obliku injekcijske formulacije, pri čemu navedeni sastav obuhvaća ariloazol-2-il-cijanoetilamino-spoj s formulom (I):
R3, R4 and R5 either, independently of one another, is hydrogen, halogen, alkyl, hydroxyalkyl, alkylthioalkyl, haloalkyl, alkyloxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkylsulfonyloxyalkyl; unsubstituted or substituted cycloalkyl, wherein the substituents may each be independent of one another and are selected from the group consisting of halogen and alkyl; unsubstituted or substituted phenyl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamine, di(alkyl)amino; or 
bilo koji od R3, R4 i R5, međusobno neovisno, predstavlja vodik, halogen, alkil, hidroksialkil, alkiltioalkil, haloalkil, alkiloksialkil, alkilsulfinilalkil, alkilsulfonilalkil, alkilsulfoniloksialkil; nesupstituirani ili supstituirani cikloalkil, pri čemu supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: halogen i alkil; nesupstituirani ili supstituirani fenil, pri čemu supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: cijano, nitro, halogen, alkil, haloalkil, alkiltio, haloalkiltio, ariltio, alkoksi, haloalkoksi, alkilkarbonil, haloalkilkarbonil, alkilsulfinil, haloalkilsulfinil, alkilsulfonil, haloalkilsulfonil, alkilamino, di(alkil)amino; ili
and R5 together with the carbon to which they are attached form a cycloalkyl ring; 
i R5 zajedno s ugljikom na kojega su priključeni, tvore cikloalkilni prsten;
is hydrogen, alkyl, alkoxyalkyl, alkylcarbonyl, alkylthiocarbonyl or unsubstituted or substituted benzyl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamine, di(alkyl)amino; 
je vodik, alkil, alkoksialkil, alkilkarbonil, alkiltiokarbonil ili nesupstituirani ili supstituirani benzil, gdje supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: cijano, nitro, halogen, alkil, haloalkil, alkiltio, haloalkiltio, ariltio, alkoksi, haloalkoksi, alkilkarbonil, haloalkilkarbonil, alkilsulfinil, haloalkilsulfinil, alkilsulfonil, haloalkilsulfonil, alkilamino, di(alkil)amino;
A parasiticidal composition according to claim 1, wherein P is C-R1 or N; Q is C-R2 or N; 
Paraziticidni sastav prema zahtjevu 1, naznačen time, da P je C-R1 ili N; Q je C-R2 ili N;
a is 1; and salts thereof. 
a je 1; i njihove soli.
A parasiticidal composition according to claim 1, wherein P is N; 
Paraziticidni sastav prema zahtjevu 1, naznačen time, da P je N;
A parasiticidal composition according to claim 1 wherein the aryloazol-2-yl-cyanoethylamine compound is selected from: 
Paraziticidni sastav prema zahtjevu 1, naznačen time, da je ariloazol-2-il-cijanoetilamino-spoj odabran od sljedećih:
A parasiticidal composition according to any preceding claim which further comprises an additional active ingredient. 
Paraziticidni sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da on nadalje obuhvaća dodatni djelatni sastojak.
A parasiticidal composition according to any preceding claim which is in the form of a sterile injectable aqueous or oleaginous suspension. 
Paraziticidni sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da se on nalazi u obliku sterilne injekcijske vodene ili uljne suspenzije.
A parasiticidal composition according to any one of claims 1 to 12 which is in the form of a sterile injectable solution. 
Paraziticidni sastav prema bilo kojem od zahtjeva 1 do 12, naznačen time, da se on nalazi u obliku sterilne injekcijske otopine.
The parasiticidal composition for use according to claim 15 wherein the endoparasitic infection is with a helminth selected from the group consisting of Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorous, Uncinaria, Wuchereria, and combinations thereof. 
Paraziticidni sastav za uporabu prema zahtjevu 15, naznačen time, da se radi o endoparazitnim infekcijama koje se prenose helmintima odabranima iz skupine koja se sastoji od sljedećih: Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorus, Uncinaria, Wuchereria i njihove kombinacije.
The parasiticidal composition for use according to claim 15 wherein the helminth is Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubriformis, Cooperia curticei, Nematodirus battus and combinations thereof. 
Paraziticidni sastav za uporabu prema zahtjevu 15, naznačen time, da helmint je Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubriformis, Cooperia curticei, Nematodirus battus i njihove kombinacije.
The parasiticidal composition for use according to claim 18 wherein the ectoparasitic infection is with an ectoparasite selected from the group consisting of fleas, ticks, mites, mosquitoes, flies, lice, blowfly and combinations thereof. 
Paraziticidni sastav za uporabu prema zahtjevu 18, naznačen time, da se radi o ektoparazitnim infekcijama koje se prenose ektoparazitima odabranima iz skupine koja se sastoji od buha, krpelji, crva, komaraca, muha, uši, muha zunzara i njihovih kombinacija.
The parasiticidal composition for use according to claim 18 wherein the ectoparasitic infection is with fleas. 
Paraziticidni sastav za uporabu prema zahtjevu 18, naznačen time, da se radi o ektoparazitnim infekcijama koje se prenose s buhama.
A method according to claim 9, characterized in that the metering member (101.102) is moved in a plane parallel to the metering plate (91,92). 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se dozirni element (101.102) pomiče u ravnini paralelnoj u odnosu na dozirnu ploču (91,92).
A protein consisting of formula I: 
Protein koji ima formulu I:
43 or a sequence having at least 90%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO. 
43 ili slijed koji je najmanje 90%, 95%, 96%, 97%, 98%, 99% istovjetan slijedu SEQ ID NO.
The vaccine of claim 11 wherein the immunogenic composition contains a protein of SEQ ID NO: 69, Protein D and a PE-PilA fusion protein, optionally LVL-735. 
Cjepivo u skladu s patentnim zahtjevom 11, naznačeno time što imunogeni pripravak sadrži protein sa SEQ ID NO: 69, Protein D i fuzijski protein PE-PilA, izborno LVL-735.
A system (1) for opening and closing a communication path between two separate environments, said system comprising: 
Sustav (1) za otvaranje i zatvaranje komunikacijskog puta između dva odvojena okoliša, gdje navedeni sustav sadrži:
• separation means (2, 7) respectively suitable for allowing and preventing, at least partially, the traversing of said path by light, air, or sound waves; 
• element za razdvajanje (2, 7), odgovarajuće pogodan za omogućavanje i sprječavanje, u najmanju ruku djelomičnog, prolaženja kroz navedeni put svjetla, zraka ili zvučnih valova;